Ligand’s Partner Gloria Biosciences Receives Approval in China for Zimberelimab for the Treatment of Recurrent or Refractory Classical Hodgkin’s Lymphoma
Retrieved on:
Monday, August 30, 2021
Research, Medical Supplies, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, PD-1, Baxter International, CHL, Biology, Merck, Research, Drug discovery, Animal, Hodgkin lymphoma, Exposition, Safety, Solution, ICH, Therapy, BI, U.S. Securities and Exchange Commission, Solubility, Heart, NSCLC, Veni, vidi, vici, Roche, GMP, Industry, Twitter, Global Vision, Antibody, AI, NMPA, NASDAQ, GSK, Gilead Sciences, Security (finance), Private Securities Litigation Reform Act, Sanofi, Progression-free survival, GxP, Acquisition, Immune system, Jazz Pharmaceuticals, Wuxi, Prostate, Ligand Pharmaceuticals, Janssen, News, Patient, Amgen, Trae tha Truth, Breakthrough therapy, Pharmaceutical industry, Vaccine, Fine chemical, Tanning (leather), Zimberelimab, OmniAb®, Gloria Biosciences, Ligand Pharmaceuticals, ZIMBERELIMAB, OMNIAB®, GLORIA BIOSCIENCES, LIGAND PHARMACEUTICALS
GloriaBio has development and commercialization rights in China with respect to zimberelimab through a sublicense agreement with Ligand's licensee Wuxi Biologics Ireland Limited.
Key Points:
- GloriaBio has development and commercialization rights in China with respect to zimberelimab through a sublicense agreement with Ligand's licensee Wuxi Biologics Ireland Limited.
- Zimberelimab is being developed by Arcus Bioscience in North America, Europe, Japan and certain other territories through a 2017 license agreement.
- GloriaBio contracted with Ligands partner WuXi Biologics to discover and develop GLS-010 using Ligand's transgenic rat platform, OmniRat.
- GloriaBio has received approval in China for zimberelimab for the treatment of recurrent or refractory cHL.